SynthesisFrontiers in endocrinology2025
Correlations between circulating adipokines and hepatocellular carcinoma: a Systematic Review and meta-analysis.
Synthesis in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Myokines in exercise‑mediated bone homeostasis: Molecular signaling mechanisms and therapeutic implications for bone disorders (Review).International journal of molecular medicine · 2026Review
- Evaluating plasma adipokines and their cognate receptors as biomarkers for non-invasive diagnosis of endometrial cancer.Bioscience reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Hepatocellular carcinoma (HCC) is among the most common malignant tumors, characterized by high incidence and mortality rates. The role of adipokines in liver diseases is increasingly recognized and involves multiple contributing factors. Therefore, we summarized the relationship between circulating adipokines and HCC to guide directions for future research. Methods: Six databases were searched, and all data were presented as standardized mean difference (SMD) or weighted mean difference (WMD). Sensitivity analysis and meta-regression were also performed. Diagnostic meta-analysis results were primarily presented using receiver operating characteristic (ROC) curves. Results: A total of 41 articles were included in this meta-analysis. HCC patients had significantly higher levels of circulating adiponectin, leptin, visfatin, and resistin compared to the controls (SMD = 1.6, 95% CI: 0.65-2.56; SMD = 2.45, 95% CI: 1.59-3.31; SMD = 2.49, 95% CI: 1.32-3.65; SMD = 4.17, 95% CI: 3.17-5.17, respectively). Conversely, circulating irisin levels in HCC patients were significantly lower than those in the control group (WMD = -1.16, 95% CI: -1.55, -0.77). Subgroup analysis identified possible sources of heterogeneity, whereas meta-regression confirmed that only the presence or absence of viral hepatitis was the source of high heterogeneity among leptin-related studies. Additionally, the meta-analysis results of diagnostic studies show that circulating visfatin demonstrates good diagnostic value for HCC, which may be helpful for clinical practice. Conclusion: There is a significant association between circulating adipokines and HCC, and the presence of viral hepatitis is an influencing factor. Most adipokines are differentially expressed in HCC patients, and some may serve as biomarkers for early diagnosis or prognostic assessment. Systematic review registration: https://www.crd.york.ac.uk/PROSPERO/, identifier CRD42023492972.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.